Rémy Duléry, Research Fellow at Harvard Medical School, Physician at the Department of Clinical Hematology and Cellular Therapy at Saint-Antoine Hospital, shared a post on LinkedIn:
“I am truly honored to present at ASH25 our study on the impact of the number of bridging therapy lines before axi-cel in LBCL, using real-world data from the DESCAR-T registry.
Bridging therapy is commonly used before CAR T-cell infusion, but whether giving additional lines improves outcomes has remained unclear. In our cohort of 777 patients, we analyzed survival, response, toxicity, and propensity-score–adjusted outcomes.
Key findings:
- Patients receiving >1 bridging line had inferior overall survival compared with those receiving only one.
- Even among patients with progressive disease after the first line, giving additional bridging did not improve survival.
- Disease status improved in only a minority of patients, while persistent hematotoxicity was more frequent with >1 line.
Overall, delaying CAR T-cell infusion to administer further bridging therapy provides limited clinical benefit, does not improve survival, and may increase toxicity risk.
I am very grateful to all participating patients, investigators, and the DESCAR-T, LYSA, and LYSARC teams for making this work possible.”
More posts featuring Rémy Duléry.
